Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280956 · ClinicalTrials.gov registry record · Phase 4
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
A Phase 4 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,000
- Enrollment target
NCT00280956 is a Phase 4 study that has completed, run by Biogen. The registered enrollment target is 2,000 participants.
The verdict
NCT00280956, a Phase 4 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.
Interventions
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2002-07 |
| Est. Completion | 2004-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280956
The ClinicalTrials.gov registry entry for NCT00280956 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which natalizumab is the first listed.
NCT00280956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00280956 about?
NCT00280956 is a clinical study titled "Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease". The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.
What is the current status of trial NCT00280956?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,000 participants. The study started on 2002-07. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00280956?
The interventions under investigation include: natalizumab (DRUG).
Who is sponsoring clinical trial NCT00280956?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.